Diagnostic Testing for Cancer Treatment | Labcorp Oncology | Labcorp
Labcorp Oncology
Clarity in critical moments
For Providers
Our comprehensive, specialized diagnostic testing menu keeps you informed throughout the continuum of care—from screening, diagnosis and prognosis to treatment options and response.
For Biopharma Partners
Our global oncology-specific expertise helps advance cancer diagnostics, drugs and devices through the full drug development continuum with speed and efficiency.
For Patients
From routine cancer screenings, to understanding hereditary cancer risk to biomarker testing to help guide cancer treatment, we are here to support you throughout your cancer journey.
Oncology trends and insights
Support at every decision point
We’ve designed our oncology team and resources to help you every step of the way—always working to advance patient care.
Oncology-specific diagnostics
Our testing menu arms you with the most modern tools to help patients through the entire care continuum—from screening and preventive care to clear cancer diagnosis to identifying optimal evidence-based treatments and tracking your patient’s response.
Global oncology development and clinical trials
We provide powerful data and advanced technologies to inform preclinical decisions and oncology model selection; design, manage and recruit for clinical trials; leverage appropriate decentralized techniques; generate ongoing real-world evidence; and perform long-term follow-up studies to support the ongoing development of your product.
Advancements in oncology are just a click away
Articles
- How a blood test is making cancer care more equitable
- Graphical summary: Rapid and reliable POLE mutation detection in endometrial cancer
- The future of monoclonal antibody development is human-relevant
- Companion diagnostic development in precision oncology: The importance of early planning and the role of next-generation sequencing
- Labcorp Perspectives Oncology (Episode 15): The Pulse of the Pathologist: Why Pathology is at a Turning Point
- Liquid biopsy in clinical practice: When, why, and for which patients?
- Detecting Molecular Residual Disease (MRD) Changes What You Can See and When You Can Act
- Risk-Reducing Interventions in Women With Pathogenic Variants in Breast Cancer Susceptibility Genes
- Labcorp Perspectives Oncology (Episode 14): Surviving and Thriving with Cancer at 16
- Pulse of the Pathologist
- Labcorp Perspectives Oncology (Episode 13): How SLiCE is speeding up cancer treatment decisions
- Leveraging a Real-World Clinicogenomic Database for Post-Sequencing Quality Assessment in Solid Tumor Comprehensive Genomic Profiling
- Why somatic and hereditary cancer testing is crucial in oncology
- How digital education improves HER2‑low awareness in metastatic breast cancer, according to a Labcorp study
- The validation of a multiple myeloma minimal residual disease flow cytometry assay for use in multi-centric clinical trials